261 related articles for article (PubMed ID: 37751103)
1. NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.
Fetzko SL; Timothy LD; Parihar R
Curr Hematol Malig Rep; 2023 Dec; 18(6):264-272. PubMed ID: 37751103
[TBL] [Abstract][Full Text] [Related]
2. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
Lin C; Horwitz ME; Rein LAM
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
[TBL] [Abstract][Full Text] [Related]
3. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
4. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
5. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
Pan S; Wang F; Jiang J; Lin Z; Chen Z; Cao T; Yang L
Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):153-162. PubMed ID: 36437159
[TBL] [Abstract][Full Text] [Related]
7. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
Goldenson BH; Hor P; Kaufman DS
Front Immunol; 2022; 13():841107. PubMed ID: 35185932
[TBL] [Abstract][Full Text] [Related]
8. Engineering the next generation of CAR-NK immunotherapies.
Biederstädt A; Rezvani K
Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
[TBL] [Abstract][Full Text] [Related]
9. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract][Full Text] [Related]
10. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
11. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
Tay SS; Carol H; Biro M
Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
[TBL] [Abstract][Full Text] [Related]
12. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.
Baghery Saghchy Khorasani A; Yousefi AM; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109041. PubMed ID: 35839565
[TBL] [Abstract][Full Text] [Related]
13. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
18. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
19. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells: a promising immunotherapy for cancer.
Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y
J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
